Prothena Corporation

Today, on @rarediseaseday, we recognize the 300 million people worldwide living with a #raredisease. At Prothena, we stand with the rare disease community – today and every day.

We’re looking forward to presenting at the @Piper_Sandler 37th Annual Healthcare Conference and the @EvercoreISI 8th Annual Healthcare Conference this week. Don’t miss our live webcasts and learn more here: bit.ly/48KpYRy

We’re presenting new preclinical data from our TDP-43 CYTOPE program at Neuroscience 2025, hosted by @SfNtweets in San Diego, CA. View the press release to learn more: bit.ly/49oSUj1

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive, and often fatal disease in which amyloid deposits accumulate in the heart. As patients often experience delays in diagnosis, continued efforts to raise awareness and develop potential solutions for those with ATTR-CM remain crucial.

#DYK that #ParkinsonsDisease is a progressive neurological disorder that becomes more common with age? Raising awareness is key to promoting early detection and vital support for those affected. Access helpful resources here: bit.ly/48LP8zO

#WorldAlzheimersMonth and #WorldAlzheimersDay serve as a reminder of the importance of awareness, education, and support for those affected. The 2025 World Alzheimer Report from @AlzDisInt offers a roadmap to reimagining life with dementia through rehabilitation, a valuable resource for individuals living with #Alzheimers. Learn more: bit.ly/4nXhBHt

We’re looking forward to presenting at the Cantor Fitzgerald Global Healthcare Conference in New York this week. Don’t miss our live webcast and learn more here: bit.ly/3K45DwH

From groundbreaking scientific discoveries to compassionate caregiving, innovative leadership, and beyond, women have made countless incredible contributions that have shaped our communities. That is why advancing equality, supporting women’s growth, and inspiring the next generation of leaders in healthcare and pharma remain essential for communities and industries everywhere. #WomensEqualityDay

Though #AlzheimersDisease impacts many families, fewer than 1 in 5 Americans say they know a lot about it. Looking to understand more about Alzheimer’s and access educational resources? Visit the @alzassociation website to learn more: bit.ly/41Eq4Gq

What an inspiring time at #AAIC2025! We were honored to join the @alzassociation and the #AlzheimersDisease community as part of our ongoing efforts to raise awareness, advance research, and bring hope to all affected by Alzheimer’s.

#BreakingNews: Today, we’re excited to share that @novonordisk successfully completed a Phase 2 trial with coramitug (formerly PRX004) and is expected to advance the program into Phase 3 development for ATTR #amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Read more: bit.ly/4opUx4T

Having conversations about #AlzheimersDisease with children helps them better understand what is happening and connect with their loved ones facing this disease. For helpful, age-appropriate resources, visit the @alzassociation website: bit.ly/4o6Mvhb

We’re headed to Toronto for #AAIC25! Alongside the @alzassociation, researchers, and Alzheimer’s experts, we’ll be taking part in important discussions on the latest advances in diagnosis, risk reduction, and treatment for #AlzheimersDisease. Learn more: bit.ly/4f1zBNn

With #dementia and #AlzheimersDisease cases projected to rise in the coming decades, especially in aging populations, raising awareness for Alzheimer’s is key for earlier intervention and reducing stigma around this neurodegenerative disease.

By the mid-21st century, #dementia cases are projected to reach 152M worldwide. Raising awareness of #AlzheimersDisease—the most common form—is crucial for driving timely diagnosis and care. What percentage of dementia cases do you think Alzheimer’s accounts for? Vote below!

#DYK millions of Americans are living with #AlzheimersDisease, impacting individuals, families, and communities across the country? Learn more about the impact of this disease by viewing the latest report provided by the @alzassociation: bit.ly/401Bu6l

At Prothena, #TheLongestDay reflects our unwavering commitment to shining light on families affected by #AlzheimersDisease and #dementia. Hear from LuPita, as she shares her hopes for a brighter future in the fight against neurodegenerative diseases: bit.ly/409oDiv

Today, we are excited to announce that our partner @Roche will advance prasinezumab into Phase 3 development in early-stage Parkinson’s disease. Prasinezumab has the potential to be the first disease-modifying treatment option for the millions of individuals living with Parkinson’s disease and their families. bit.ly/3STJjr6